US Stock MarketDetailed Quotes

NKTR Nektar Therapeutics

Watchlist
  • 0.8200
  • -0.0580-6.61%
Close Mar 10 16:00 ET
  • 0.8500
  • +0.0300+3.66%
Post 20:01 ET
151.26MMarket Cap-0.98P/E (TTM)

Nektar Therapeutics Key Stats

Nektar Therapeutics Q4 2024 Estimates Date

Currency:USDMar 12, 2025

Estimate YoY
Revenue
36.66M
+53.48%
EPS
-0.14
+38.56%
Buy

Feb 28, 2025

Nektar Therapeutics Earnings Estimates

Revenue

EPS

EBIT

Revenue is based on 6 analyst forecasts. Estimate data is from S&P, and actual data is from Income Statement

Currency: USD

Actual
Estimate
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 22.390M--
Mar 12, 20252024/Q4-- / 36.658M--
Nov 7, 20242024/Q324.124M / 18.280M--
Aug 8, 20242024/Q223.489M / 17.545M--
May 9, 20242024/Q121.639M / 15.342M--
DatePeriodRevenue/EstimateEarnings Call
--2025/Q1-- / 22.390M--
Mar 12, 20252024/Q4-- / 36.658M--
Nov 7, 20242024/Q324.124M / 18.280M--
Aug 8, 20242024/Q223.489M / 17.545M--
May 9, 20242024/Q121.639M / 15.342M--

Unlock Free Earnings Estimates

Nektar Therapeutics Earnings Reports

Read more

Trending Stocks
Fed Rate Cut Beneficiaries Fed Rate Cut Beneficiaries

Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data. Stocks that are expected to benefit from a Federal Reserve rate cut. Information is provided by Futu and is a non-exhaustive list of all thematic stocks for reference purposes only. This section presents the top 5 stocks in Fed Rate Cut Beneficiaries, ranked from highest to lowest based on real-time market data.

Analysis

Analyst Rating

Updated: Feb 28, 2025

Buy

  • Buy

    66.67%
  • Hold

    16.67%
  • Sell

    16.67%

Price Target

No Data